临床外科杂志 ›› 2021, Vol. 29 ›› Issue (8): 743-747.doi: 10.3969/j.issn.1005-6483.2021.08.014

• • 上一篇    下一篇

自体肿瘤浸润淋巴细胞联合抗程序性死亡受体1单抗治疗晚期肝癌的临床研究

  

  1. 华中科技大学同济医学院附属同济医院肝脏外科中心
  • 出版日期:2021-08-20 发布日期:2021-08-20

Clinical application of autologous tumor infiltrating lymphocytes combined with antiPD1 antibody in the treatment of advanced hepatocellular carcinoma

  • Online:2021-08-20 Published:2021-08-20

摘要: 目的:研究自体肝癌肿瘤浸润淋巴细胞(TIL)体外扩增后回输联合抗PD1单抗治疗晚期肝癌的安全性及有效性。方法:选择肝癌术后复发不能再次根治切除或伴有肝外转移的肝癌病人为研究对象。从切除的肿瘤中分离TIL、或从腹腔镜下获取的肿瘤组织中获取TIL,体外分离扩增,当TIL扩增至少达到2×109个时进行回输,输注后联用抗PD1单抗,并持续给予白细胞介素(IL)2注射维持TIL活性,观察不良反应及初步疗效。结果:对4例晚期肝癌病人成功分离、扩增及回输TIL。4例病人均显示出良好的耐受性,不良反应小。目前中位随访7.5个月,2例病人存活,生存的病人中1例肺转移灶消失,另1例肾上腺转移灶部分坏死。另2例最早入组的肝癌病人因入组时肿瘤负荷较大,分期较晚,疾病进展死亡,生存时间分别为3个月和6个月。结论:自体TIL体外扩增回输联合抗PD1单抗治疗晚期肝癌病人安全可行,初步观察其有效,长期疗效值得深入研究。TIL体外扩增回输联合抗PD1单抗治疗可能成为一种治疗肝癌的新方法。

关键词: 肝癌, 肿瘤浸润性淋巴细胞, 抗PD1单抗, 免疫治疗

Abstract: Objective:To study the safety and efficacy of clinical application of autologous tumor infiltrating lymphocytes (TIL) after in vitro amplification,in combination with antiPD1 monoclonal antibody for the treatment of advanced hepatocellular carcinoma (HCC).Methods:The patients with postoperative recurrence or extrahepatic metastasis that are not operable were selected for the study.TIL were isolated from the tumor samples obtained through local resection under laparoscopy,and TIL were amplified up to 2×109 cells and administered intravenously to the patients.After TIL infusion,antiPD1 monoclonal antibody injection was followed every 21 days,and IL2 was continuously injected to maintain the activity of TIL for two weeks,and the adverse effects and treatment efficacy were evaluated.Results:TIL were successfully isolated,amplified and administered in 4 patients with advanced liver cancers.All 4 patients showed good tolerance and minor adverse effects.At present,the median followup period was 7.5 months,2 patients are under observation,one with lung metastatic lesion disappearing and the another with adrenal metastatic lesion partially necrotizing.The other 2 patients died due to high tumor load and advanced stage of tumor,and their survival time was 3 months and 6 months,respectively.Conclusion:TIL amplification and reinfusion combined with antiPD1 monoclonal antibody is safe and feasible in the treatment of advanced HCC,and the longterm efficacy requires further studies.Application of TIL amplified in vitro combined with antiPD1 monoclonal antibody is likely a hopeful new therapy for HCC.

Key words: hepatocellular carcinoma, tumor infiltrating lymphocytes, antiPD1 monoclonal antibody, immunotherapy 

[1] 孙启刚, 符策雄, 郑进方. 绕肝悬吊前入路右半肝切除术在肝癌手术中的应用研究[J]. 临床外科杂志, 2021, 29(8): 748-750.
[2] 马钊, 姜宏景. 食管鳞癌新辅助治疗研究进展[J]. 临床外科杂志, 2021, 29(8): 784-787.
[3] 潘乐玉, 郭德良, 张玉仙等. 肝动脉结扎联合门静脉部分阻断对肝再生及肝细胞癌生长的影响[J]. 临床外科杂志, 2021, 29(4): 367-371.
[4] 冯浩洁 姚颐 耿庆. 美国国家综合癌症网络临床实践指南:非小细胞肺癌(2021V1)更新解读[J]. 临床外科杂志, 2021, 29(1): 25-28.
[5] 国际肝胆胰协会中国分会 全国肝病和肝癌大数据联盟. 原发性肝癌临床标准化术语[J]. 临床外科杂志, 2020, 28(8): 722-724.
[6] 鲍伟. 功能性残余肝脏体积与脾脏体积比对病人术后肝功能不全以及肝功能恢复的预测价值[J]. 临床外科杂志, 2020, 28(8): 750-752.
[7] 滕啸 胡坚. 非小细胞肺癌新辅助免疫治疗前景[J]. 临床外科杂志, 2020, 28(7): 608-610.
[8] 张帆 谭锋维 薛奇 高树庚. 免疫检查点抑制剂在非小细胞肺癌新辅助治疗中的现状[J]. 临床外科杂志, 2020, 28(7): 611-614.
[9] 邓宇 郝博 耿庆. 小细胞肺癌治疗现状及展望[J]. 临床外科杂志, 2020, 28(7): 696-699.
[10] 黄志勇, 陈孝平. 肝硬化与肝癌肝切除的科学决策[J]. 临床外科杂志, 2019, 27(8): 631-633.
[11] 张海峰, 宋栋达, 刘荣. 达芬奇机器人右半肝切除技巧与经验[J]. 临床外科杂志, 2019, 27(8): 634-637.
[12] 肖永胜, 周俭. 肝移植术后肝癌复发转移与PD-1/PD-L1抑制剂免疫治疗[J]. 临床外科杂志, 2019, 27(8): 642-645.
[13] 严峻, 柏淳, 李锋, 傅文喜, 余小红. 经皮肝动脉化疗栓塞术联合索拉非尼治疗肝癌的疗效及安全性观察[J]. 临床外科杂志, 2019, 27(8): 668-670.
[14] 张嘉凯, 李捷, 张水军. 肝癌肝移植研究进展[J]. 临床外科杂志, 2019, 27(8): 715-717.
[15] 卢远响, 陶连元, 马家豪, 肖二卫, 李德宇. 吲哚菁绿荧光融合影像技术在腹腔镜肝癌切除中的应用及展望[J]. 临床外科杂志, 2019, 27(8): 718-720.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 杨雁灵, 刘世茂, 陶开山, 岳树强, 窦科峰. 急诊胰十二指肠切除治疗严重胰头十二指肠外伤[J]. 临床外科杂志, 2019, 27(12): 1021 -1023 .
[2] 宋洋 张恩刚 蔡廷江 王栋 郝小可. 数字成型钛网早期修补对颅骨缺损术后康复及美学效果的影响[J]. 临床外科杂志, 2021, 29(5): 485 -488 .
[3] . 目录[J]. 临床外科杂志, 2021, 29(8): 701 .
[4] 何文武, 韩泳涛. 对CheckMate 577:纳武单抗在食管及食管胃结合部癌术后辅助治疗中的作用的述评[J]. 临床外科杂志, 2021, 29(8): 701 -703 .
[5] 李志刚. 磁性括约肌增强器治疗胃食管反流的中国经验[J]. 临床外科杂志, 2021, 29(8): 704 -706 .
[6] 柳硕岩, 何皓, 王枫. 胸段食管鳞癌日本食管协会和国际抗癌联盟分期的比较和思考[J]. 临床外科杂志, 2021, 29(8): 707 -711 .
[7] 郑浩, 张仁泉. 浅谈早期食管癌的微创治疗[J]. 临床外科杂志, 2021, 29(8): 711 -713 .
[8] 刘继辉, 孙明, 余兵. 纵隔负压引流管在经右胸途径食管癌手术中的应用[J]. 临床外科杂志, 2021, 29(8): 714 -716 .
[9] 周存荣, 黄陈军, 蔡强. Flex三维胸腔镜肺叶切除及淋巴结清扫术治疗原发性肺癌的疗效及安全性分析[J]. 临床外科杂志, 2021, 29(8): 717 -720 .
[10] 尹露, 王恒, 王健等. 腹腔镜胆囊切除术中发生二氧化碳气栓的麻醉处理一例[J]. 临床外科杂志, 2021, 29(8): 720 -721 .